DAFTAR PUSTAKA
Anvari, K., Toussi, M. S., Shahidsales, S., Motlagh, F., & Reza, M. (2016). Treatment Outcomes and Prognostic Factors in Adult Astrocytoma: In North East of Iran. Iran J Cancer Prev 2016 August; 9(4): e4099.
Berger, M. S., Hervey-Jumper, S., & Wick, W. (2016). Astrocytic gliomas WHO grades II and III. Handbook of Clinical Neurology, 134, 345–360. http://doi.org/10.1016/B978-0-12-802997-8.00021-9
Chen, C. Q., Liao, W. H., Chen, C. Y., Wang, X., & LIU, F. (2004). Correlation between peritumoral edema on MRI, VEGF expression, MVD and pathological grading in astrocytomas. China J Modern
Darweesh, M.F., Salam, L.O.A., & Negm, M.S. (2016). Evaluation of the Proliferation Marker Ki-67 in Glioblastoma and its Correlation with Histopahtological Findings. Academic Journal of Cancer Research 2016 9 (2): 13-18
Djordjevic, G., Mozetic, V., Mozetic, D. V., et al. (2007). Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathology - Research and Practice 203 (2007) 99 - 106
Farhat. (2009). Vascular Endothelial Growth Factor pada Karsinoma Nasofaring.
Majalah Kedokteran Nusantara Vol 42 No 1 , 59-65.
Habberstad, A. H., Gulati, S., & Torp, S. H. (2011). Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an
http://doi.org/10.1186/1746-1596-6-43
Hu, X., Miao, W., Zou, Y., Zhang, W., Zhang, Y., & Liu, H. (2013). Expression of p53, epidermal growth factor receptor, Ki-67 and O6
Jian-wei, P., Ren-ya, Z., Ying, T., & Yong-Qing, Z. (2005). Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. Journal of Zhejiang
-methylguanine-DNA methyltransferase in human gliomas. Oncology Letters, 6(1), 130–134. http://doi.org/10.3892/ol.2013.1317
Johannessen, A. L., & Torp, S. H. (2006). The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathology Oncology Research : POR,
12(3), 143–147.
Li, B.-J., Zhu, Z.-H., Wang, J.-Y., Hou, J.-H., Zhao, J.-M., Zhang, P.-Y., et al. (2004). [Expression correlation of Ki67 to P53,VEGF,and C-erbB-2 genes in breast cancer and their clinical significances]. Ai Zheng = Aizheng = Chinese Journal of Cancer, 23(10), 1176–1179.
Licht, T., & Kesbet, E. (2013). Delienating multiple functions of VEGF-A in adult brain. Cell. Mol. Life Sci 70 , 1727-1737.
of tumours of the central nervous system. Acta Neuropathologica, 114(2), 97– 109. http://doi.org/10.1007/s00401-007-0243-4
Louis, D. N., Perry, A., Reifenberger, G., Deimling, von, A., Figarella-Branger, D., Cavenee, W. K., et al. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 131(6), 803–820. http://doi.org/10.1007/s00401-016-1545-1
Machein, M. R., & Plate, K. H. (2000). VEGF in brain tumors. Journal of Neuro-Oncology, 50(1-2), 109–120.
Nagasawa, D. T., Chow, F., Yew, A., Kim, W., Cremer, N., & Yang, I. (2012). Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme. Neurosurgery Clinics of North America, 23(2), 307–322. http://doi.org/10.1016/j.nec.2012.01.007
Oehring, R. D., Miletic, M., Valter, M. M., Pietsch, T., Neumann, J., Fimmers, R., & Schlegel, U. (1999). Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor? Journal of Neuro-Oncology, 45(2), 117–125.
Omuro, A. (2013). Glioblastoma and Other Malignant Gliomas. Jama, 310(17), 1842–9. http://doi.org/10.1001/jama.2013.280319
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., et al. (2013). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro-Oncology, 15(suppl 2), ii1–ii56. http://doi.org/10.1093/neuonc/not151
(2014). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncology, 16 Suppl 4(suppl 4), iv1–63. http://doi.org/10.1093/neuonc/nou223
Perry, A., & Wesseling, P. (2016). Histologic classification of gliomas. Handbook of Clinical Neurology, 134, 71–95. http://doi.org/10.1016/B978-0-12-802997-8.00005-0
Ranjan, M., Santosh, V., Tandon, A., Anandh, B., Sampath, S., Devi, B. I., and Chandramouli, B. A. (2011). Factors predicting progression of low-grade diffusely infiltrating astrocytoma. Neurology India, 59(2), 248–253. http://doi.org/10.4103/0028-3886.79137
Reifenberger, G., Blümcke, I., Pietsch, T., & Paulus, W. (2010). Pathology and Classification of Tumors of the Nervous System. In Oncology of CNS Tumors
(pp. 3–75). Berlin, Heidelberg: Springer Berlin Heidelberg. http://doi.org/10.1007/978-3-642-02874-8_1
RUAN, Y., WAG, G., & WANG, Y. (2003). Study on the expression of VEGF and Ki-67 related to malignant transformation of astrocytoma. Medicine and Pharmacy of Yunnan.
Saha, R., Chatterjee, U., Mandal, S., Saha, K., Chatterjee, S., & Ghosh, S. N. (2014). Expression of phosphatase and tensin homolog, epidermal growth factor receptor, and Ki-67 in astrocytoma: A prospective study in a tertiary care hospital. Indian Journal of Medical and Paediatric Oncology, 35(2), 149–155. http://doi.org/10.4103/0971-5851.138983
551–564. http://doi.org/10.1111/j.1750-3639.2008.00192.
Schneider, I. M., Schenider, F. T., & Plate, K. H. (2013). Brain homeostasis: VEGF receptor 1 and 2 - two equal brothers in mine. Cell. Mol. Life. Sci 70 , 1705-1725.
Schröder, R., Feisel, K. D., & Ernestus, R. I. (2002). Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas. Journal of Neuro-Oncology.
Sengupta, S., Chatterjee, U., Banerjee, U., Ghosh, S., Chatterjee, S., & Ghosh, A. K. (2012). A study of histopathological spectrum and expression of Ki-67, TP53 in primary brain tumors of pediatric age group. Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of
Medical & Paediatric Oncology, 33(1), 25–31. http://doi.org/10.4103/0971-5851.96965
Shaffrey, M. E., Farace, E., Schiff, D., Larner, J. M., Mut, M., & Lopes, M. B. S. (2005). The Ki-67 labeling index as a prognostic factor in Grade II oligoastrocytomas. Journal of Neurosurgery, 102(6), 1033–1039. http://doi.org/10.3171/jns.2005.102.6.1033
Takei, H., Bhattacharjee, M. B., Rivera, A., Dancer, Y., & Powell, S. Z. (2007). New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors.
Archives of Pathology & Laboratory Medicine, 131(2), 234–241. http://doi.org/10.1043/1543-2165(2007)131[234:NIMITE]2.0.CO;2
astrocytomas. Journal of Cancer Research and Therapeutics, 10(3), 641–645. http://doi.org/10.4103/0973-1482.139154
W, Wang., B, Mao., H, Bu.(1999). Expression of vascular endothelial growth factor in brain astrocytoma and its clinical evaluation. Hua Xi Yi Ke Da Xue Xue Bao 1999 Mar; 30(1) : 88-91
Wirsching, H.-G., Galanis, E., & Weller, M. (2016). Glioblastoma. Handbook of Clinical Neurology, 134, 381–397. http://doi.org/10.1016/B978-0-12-802997-8.00023-2
Derajat * Mortalitas Crosstabulation
Count
Mortalitas
Total Hidup Meninggal
Derajat 1 9 0 9
2 6 0 6
